There were 1,366 press releases posted in the last 24 hours and 399,943 in the last 365 days.
FDA Drug Competition Action Plan | Closing loopholes that allow brand-name drug companies to “game” FDA rules in ways that delay the generic competition Congress intended
The third component of the Drug Competition Action Plan is aimed at reducing the so-called “gaming” that frustrates and delays generic drug approvals and extends brand monopolies beyond what Congress intended with the Hatch-Waxman Amendments of 1984. Such practices upset the careful balance that Congress sought between product innovation and access and can make the development and approval process unpredictable, and potentially more costly, for generic manufacturers.
To view the guidances listed below, go to Guidances for Drugs and filter by category Drug Competition Action Plan
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability
for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this
article. If you have any complaints or copyright issues related to this article, kindly contact the author above.